Table 5.
Clinical characteristics and metabolic profile of GALNT2 rs4846914 genotypes in overweight/obese and non-obese control subjects.
| Overweight/Obese control | Non-obese control | |||||
|---|---|---|---|---|---|---|
| GG (262) | GA (161) | AA (29) | GG (104) | GA (56) | AA (14) | |
| Clinical characteristics | ||||||
| Age (years) | 35.25 ± 3.81 | 36.19 ± 7.1 | 35.69 ± 4.19 | 34.56 ± 4.37 | 34.23 ± 4.22 | 35.19 ± 2.25 |
| Gestation age (weeks) | 39.30 ± 0.90 | 39.19 ± 1.16 | 39.20 ± 0.90 | 39.31 ± 0.86 | 38.97 ± 0.95 | 39.24 ± 0.88 |
| Prepregnancy BMI (kg/m2) | 21.75 ± 2.77 | 22.1 ± 2.21 | 22.30 ± 3.15 | 18.66 ± 2.15 | 18.84 ± 1.37 | 18.71 ± 1.25 |
| Weight gain during pregnancy (kg) | 15.07 ± 5.03 | 14.01 ± 3.92a,* | 14.29 ± 4.39 | 12.11 ± 3.12 | 12.36 ± 3.48 | 11.4 ± 2.95 |
| Delivery BMI (kg/m2) | 27.77 ± 2.02 | 27.64 ± 2.10 | 28.00 ± 3.34 | 23.36 ± 2.36 | 23.56 ± 1.06 | 23.11 ± 0.92 |
| Neonatal birth height (cm) | 49.68 ± 2.29 | 49.87 ± 1.67 | 50.04 ± 1.60 | 49.53 ± 1.86 | 49.31 ± 1.80 | 49.90 ± 1.67 |
| Neonatal birth Weight (g) | 3450.76 ± 1654.66 | 3360.42 ± 355.90 | 3415.66 ± 382.76 | 3277.62 ± 358.52 | 3211.81 ± 337.84 | 3239.00 ± 363.08 |
| SBP (mmHg) | 115.94 ± 10.41 | 114.37 ± 10.27 | 114.04 ± 9.63 | 112.11 ± 9.38 | 111.79 ± 9.88 | 112.48 ± 10.08 |
| DBP (mmHg) | 72.77 ± 7.86 | 72.21 ± 7.99 | 71.20 ± 7.36 | 71.92 ± 8.02 | 70.76 ± 11.66 | 71.43 ± 8.36 |
| Metabolic profile | ||||||
| Fasting Ins (pmol/L) | 76.06 ± 40.79 | 69.31 ± 35.46 | 78.72 ± 41.08 | 59.47 ± 40.02 | 67.82 ± 38.99 | 77.02 ± 39.01 |
| Fasting Glu (mmol/L) | 4.21 ± 0.56 | 4.15 ± 0.59 | 4.18 ± 0.72 | 4.09 ± 0.71 | 4.15 ± 0.62 | 4.38 ± 0.49 |
| HOMA-IR | 2.22 ± 1.60 | 1.97 ± 1.22 | 2.16 ± 1.27 | 1.85 ± 2.48 | 1.79 ± 1.24 | 2.30 ± 1.48 |
| Triglycerides (mmol/L) | 3.79 ± 1.60 | 3.58 ± 1.49 | 3.64 ± 1.40 | 3.32 ± 1.14 | 3.56 ± 1.24 | 3.27 ± 1.00 |
| TC (mmol/L) | 6.03 ± 1.13 | 5.90 ± 1.16 | 5.70 ± 1.25 | 6.08 ± 1.21 | 6.42 ± 1.22 | 6.37 ± 1.27 |
| HDL-C (mmol/L) | 1.99 ± 0.41 | 1.91 ± 0.42 | 1.94 ± 0.53 | 2.05 ± 0.51 | 2.16 ± 0.46 | 2.22 ± 0.49 |
| LDL-C (mmol/L) | 3.12 ± 1.11 | 3.09 ± 0.95 | 2.85 ± 1.05 | 3.24 ± 0.93 | 3.46 ± 1.07 | 3.32 ± 1.17 |
| non-HDLC (mmol/L) | 4.10 ± 1.20 | 3.96 ± 0.95 | 3.75 ± 0.92 | 4.10 ± 0.97 | 4.30 ± 1.00 | 4.55 ± 1.26 |
| Atherogenic index | 2.10 ± 0.67 | 2.12 ± 0.66 | 1.85 ± 0.63 | 1.97 ± 0.75 | 2.02 ± 0.67 | 2.13 ± 0.54 |
| TG/HDL-C | 2.08 ± 0.99 | 1.93 ± 0.79 | 1.83 ± 0.94 | 1.66 ± 0.74 | 1.72 ± 0.81 | 1.67 ± 0.55 |
| apoA1 (g/L) | 2.47 ± 0.48 | 2.35 ± 0.42a,** | 2.39 ± 0.38 | 2.39 ± 0.47 | 2.47 ± 0.42 | 2.53 ± 0.43 |
| apoB (g/L) | 1.16 ± 0.28 | 1.15 ± 0.26 | 1.11 ± 0.31 | 1.17 ± 0.28 | 1.25 ± 0.30 | 1.19 ± 0.33 |
| apoB/apoA1 ratio | 0.54 ± 0.16 | 0.55 ± 0.15 | 0.50 ± 0.18 | 0.55 ± 0.18 | 0.58 ± 0.15 | 0.63 ± 0.17 |
a
compared with GG genotype carriers in the same group, *p < 0.05, **p < 0.01.